| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 34 | 2019 | 128 | 5.140 |
Why?
|
| Toxoplasma | 15 | 2024 | 30 | 4.710 |
Why?
|
| Protozoan Proteins | 11 | 2024 | 47 | 3.240 |
Why?
|
| Genetic Predisposition to Disease | 29 | 2019 | 654 | 2.900 |
Why?
|
| Skin Neoplasms | 21 | 2019 | 118 | 2.300 |
Why?
|
| Polymorphism, Single Nucleotide | 27 | 2019 | 537 | 2.060 |
Why?
|
| Cyclic GMP | 4 | 2022 | 27 | 1.490 |
Why?
|
| Genome-Wide Association Study | 21 | 2019 | 226 | 1.470 |
Why?
|
| Reperfusion Injury | 15 | 2014 | 31 | 1.430 |
Why?
|
| Melanocytes | 6 | 2018 | 12 | 1.380 |
Why?
|
| Toxoplasmosis | 6 | 2021 | 9 | 1.370 |
Why?
|
| Mutation | 11 | 2017 | 817 | 1.150 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 2 | 2017 | 6 | 1.100 |
Why?
|
| Parasites | 2 | 2024 | 9 | 1.020 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2017 | 6 | 0.970 |
Why?
|
| Acute Kidney Injury | 12 | 2014 | 73 | 0.950 |
Why?
|
| Apicomplexa | 1 | 2024 | 4 | 0.930 |
Why?
|
| Protein Kinases | 1 | 2024 | 143 | 0.850 |
Why?
|
| Proteomics | 2 | 2024 | 177 | 0.850 |
Why?
|
| Quantitative Trait Loci | 4 | 2019 | 53 | 0.840 |
Why?
|
| Humans | 87 | 2019 | 26826 | 0.780 |
Why?
|
| Promoter Regions, Genetic | 4 | 2017 | 330 | 0.750 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2014 | 49 | 0.740 |
Why?
|
| Animals | 39 | 2024 | 9960 | 0.710 |
Why?
|
| Uveal Neoplasms | 3 | 2019 | 8 | 0.700 |
Why?
|
| GA-Binding Protein Transcription Factor | 2 | 2017 | 2 | 0.700 |
Why?
|
| Telomerase | 7 | 2017 | 37 | 0.690 |
Why?
|
| Organelles | 1 | 2020 | 6 | 0.690 |
Why?
|
| Prosthesis Coloring | 1 | 2019 | 1 | 0.680 |
Why?
|
| Composite Resins | 1 | 2019 | 23 | 0.670 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2014 | 14 | 0.640 |
Why?
|
| Guanylate Cyclase | 1 | 2018 | 14 | 0.640 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 8 | 0.580 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2019 | 75 | 0.580 |
Why?
|
| Introns | 1 | 2017 | 41 | 0.580 |
Why?
|
| Kidney Neoplasms | 4 | 2019 | 98 | 0.560 |
Why?
|
| Succinate Dehydrogenase | 1 | 2017 | 7 | 0.560 |
Why?
|
| Activin Receptors, Type I | 2 | 2014 | 5 | 0.560 |
Why?
|
| Cell Proliferation | 2 | 2017 | 771 | 0.560 |
Why?
|
| Radiation Dosage | 2 | 2015 | 53 | 0.540 |
Why?
|
| Mice | 29 | 2024 | 4406 | 0.540 |
Why?
|
| Serum Albumin | 1 | 2016 | 35 | 0.520 |
Why?
|
| Cell Membrane | 1 | 2017 | 235 | 0.510 |
Why?
|
| Calcium Signaling | 1 | 2016 | 68 | 0.510 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2019 | 444 | 0.500 |
Why?
|
| Germ-Line Mutation | 6 | 2019 | 29 | 0.500 |
Why?
|
| Genetic Loci | 8 | 2017 | 75 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 18 | 2019 | 1475 | 0.490 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 22 | 0.470 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2014 | 11 | 0.470 |
Why?
|
| Mutation, Missense | 3 | 2012 | 67 | 0.460 |
Why?
|
| Base Sequence | 9 | 2017 | 573 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 464 | 0.450 |
Why?
|
| RNA Splice Sites | 2 | 2013 | 5 | 0.450 |
Why?
|
| Female | 35 | 2019 | 14462 | 0.440 |
Why?
|
| Signal Transduction | 11 | 2020 | 1344 | 0.440 |
Why?
|
| Male | 42 | 2019 | 12869 | 0.430 |
Why?
|
| Lymphoma, Follicular | 2 | 2010 | 13 | 0.420 |
Why?
|
| Paraganglioma | 1 | 2012 | 2 | 0.420 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 563 | 0.410 |
Why?
|
| Lung | 3 | 2012 | 349 | 0.410 |
Why?
|
| Telomere | 4 | 2017 | 28 | 0.400 |
Why?
|
| Receptor, Adenosine A1 | 4 | 2013 | 4 | 0.400 |
Why?
|
| Models, Theoretical | 1 | 2013 | 129 | 0.400 |
Why?
|
| Kidney | 9 | 2013 | 275 | 0.390 |
Why?
|
| RNA, Messenger | 12 | 2013 | 646 | 0.390 |
Why?
|
| Liver Diseases | 6 | 2013 | 51 | 0.380 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2019 | 29 | 0.380 |
Why?
|
| Transcription Factors | 7 | 2017 | 509 | 0.370 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2010 | 70 | 0.370 |
Why?
|
| Cell Line, Tumor | 9 | 2017 | 1259 | 0.370 |
Why?
|
| Phosphorylation | 4 | 2024 | 560 | 0.370 |
Why?
|
| Telomere-Binding Proteins | 3 | 2014 | 4 | 0.360 |
Why?
|
| Receptors, Lysosphingolipid | 5 | 2013 | 8 | 0.350 |
Why?
|
| Isoflurane | 3 | 2014 | 5 | 0.340 |
Why?
|
| Anesthetics, Inhalation | 3 | 2014 | 5 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2009 | 18 | 0.330 |
Why?
|
| Interleukin-11 | 3 | 2013 | 6 | 0.330 |
Why?
|
| Genetic Variation | 2 | 2010 | 229 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 146 | 0.320 |
Why?
|
| Skin Pigmentation | 2 | 2019 | 10 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2008 | 5 | 0.310 |
Why?
|
| Molecular Sequence Data | 9 | 2016 | 1036 | 0.300 |
Why?
|
| Candidiasis | 1 | 2008 | 20 | 0.300 |
Why?
|
| Gene Expression Profiling | 7 | 2017 | 439 | 0.300 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 29 | 0.300 |
Why?
|
| Pedigree | 9 | 2016 | 153 | 0.300 |
Why?
|
| Cells, Cultured | 5 | 2018 | 970 | 0.300 |
Why?
|
| Papio | 1 | 2008 | 78 | 0.300 |
Why?
|
| Bacterial Infections | 1 | 2008 | 54 | 0.290 |
Why?
|
| Melanins | 2 | 2017 | 6 | 0.290 |
Why?
|
| Genome, Protozoan | 3 | 2017 | 5 | 0.280 |
Why?
|
| Linkage Disequilibrium | 3 | 2019 | 107 | 0.270 |
Why?
|
| Case-Control Studies | 10 | 2017 | 700 | 0.270 |
Why?
|
| Kidney Tubules, Proximal | 4 | 2013 | 13 | 0.260 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 2 | 2017 | 14 | 0.250 |
Why?
|
| Interleukin-17 | 4 | 2012 | 51 | 0.240 |
Why?
|
| Risk Factors | 8 | 2019 | 2010 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 5 | 2014 | 364 | 0.240 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 481 | 0.240 |
Why?
|
| Apicoplasts | 1 | 2024 | 1 | 0.230 |
Why?
|
| Models, Molecular | 2 | 2017 | 441 | 0.230 |
Why?
|
| Substrate Specificity | 1 | 2024 | 149 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2017 | 114 | 0.230 |
Why?
|
| 5'-Nucleotidase | 2 | 2014 | 13 | 0.220 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 100 | 0.220 |
Why?
|
| Adenosine | 5 | 2014 | 33 | 0.220 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 245 | 0.220 |
Why?
|
| DNA Mutational Analysis | 5 | 2014 | 90 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2017 | 465 | 0.220 |
Why?
|
| Cross-Cultural Comparison | 1 | 2003 | 20 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2006 | 190 | 0.210 |
Why?
|
| Apoptosis | 11 | 2013 | 739 | 0.210 |
Why?
|
| Community Participation | 1 | 2003 | 25 | 0.210 |
Why?
|
| Health Services Research | 1 | 2003 | 40 | 0.210 |
Why?
|
| Adult | 13 | 2018 | 7382 | 0.210 |
Why?
|
| Protein Isoforms | 3 | 2019 | 117 | 0.210 |
Why?
|
| BRCA2 Protein | 3 | 2019 | 18 | 0.210 |
Why?
|
| Cell Movement | 2 | 2021 | 353 | 0.200 |
Why?
|
| Nucleotides, Cyclic | 1 | 2022 | 3 | 0.200 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2022 | 14 | 0.200 |
Why?
|
| Energy Transfer | 1 | 2021 | 7 | 0.200 |
Why?
|
| Ischemia | 3 | 2012 | 83 | 0.200 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2013 | 6 | 0.200 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 16 | 0.190 |
Why?
|
| Nevus | 2 | 2018 | 4 | 0.190 |
Why?
|
| Phenols | 1 | 2001 | 22 | 0.190 |
Why?
|
| Cyclic AMP | 1 | 2022 | 80 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2003 | 172 | 0.190 |
Why?
|
| Procollagen-Proline Dioxygenase | 2 | 2012 | 3 | 0.190 |
Why?
|
| Uterus | 1 | 2001 | 31 | 0.190 |
Why?
|
| Molecular Chaperones | 1 | 2001 | 49 | 0.190 |
Why?
|
| Alleles | 6 | 2019 | 345 | 0.190 |
Why?
|
| Genome, Human | 3 | 2017 | 67 | 0.190 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2001 | 61 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 507 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 338 | 0.180 |
Why?
|
| Research Personnel | 1 | 2001 | 34 | 0.180 |
Why?
|
| Tattooing | 1 | 2000 | 6 | 0.180 |
Why?
|
| Telomere Homeostasis | 2 | 2017 | 10 | 0.180 |
Why?
|
| Peer Group | 1 | 2001 | 36 | 0.180 |
Why?
|
| Calcium | 1 | 2021 | 231 | 0.180 |
Why?
|
| Estradiol | 1 | 2001 | 174 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 131 | 0.180 |
Why?
|
| Enzyme Inhibitors | 4 | 2015 | 247 | 0.180 |
Why?
|
| Gene Expression | 4 | 2017 | 406 | 0.180 |
Why?
|
| Immunoblotting | 3 | 2017 | 122 | 0.170 |
Why?
|
| Gene Editing | 2 | 2017 | 19 | 0.170 |
Why?
|
| Aged | 9 | 2018 | 5166 | 0.170 |
Why?
|
| Smoking Prevention | 1 | 2001 | 87 | 0.170 |
Why?
|
| RNA, Neoplasm | 3 | 2017 | 24 | 0.170 |
Why?
|
| Amino Acid Sequence | 6 | 2014 | 674 | 0.170 |
Why?
|
| Adolescent Behavior | 1 | 2000 | 67 | 0.170 |
Why?
|
| Luciferases | 1 | 2020 | 49 | 0.170 |
Why?
|
| Dental Restoration, Permanent | 1 | 2019 | 9 | 0.170 |
Why?
|
| Color | 1 | 2019 | 22 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 17 | 0.170 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 23 | 0.170 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2018 | 46 | 0.170 |
Why?
|
| Middle Aged | 10 | 2018 | 6817 | 0.160 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 273 | 0.160 |
Why?
|
| Alcohol Drinking | 1 | 2001 | 162 | 0.160 |
Why?
|
| Genetics, Population | 1 | 2019 | 72 | 0.160 |
Why?
|
| Health Promotion | 1 | 2001 | 169 | 0.160 |
Why?
|
| P-type ATPases | 1 | 2018 | 1 | 0.160 |
Why?
|
| Hemeproteins | 1 | 2018 | 8 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2019 | 58 | 0.160 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 1 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2013 | 27 | 0.160 |
Why?
|
| Population Groups | 1 | 2018 | 12 | 0.150 |
Why?
|
| Liver | 5 | 2013 | 415 | 0.150 |
Why?
|
| Interferon Regulatory Factors | 1 | 2018 | 57 | 0.150 |
Why?
|
| Virulence | 1 | 2018 | 144 | 0.150 |
Why?
|
| Host-Parasite Interactions | 2 | 2017 | 10 | 0.150 |
Why?
|
| Inflammation | 5 | 2014 | 601 | 0.150 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 18 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 26 | 0.150 |
Why?
|
| Odds Ratio | 3 | 2019 | 230 | 0.150 |
Why?
|
| Gene Flow | 1 | 2017 | 11 | 0.150 |
Why?
|
| Fibroblasts | 1 | 2018 | 152 | 0.150 |
Why?
|
| INDEL Mutation | 1 | 2017 | 7 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2018 | 114 | 0.150 |
Why?
|
| ABO Blood-Group System | 1 | 2017 | 7 | 0.140 |
Why?
|
| Calmodulin | 1 | 2017 | 9 | 0.140 |
Why?
|
| Acylation | 1 | 2017 | 10 | 0.140 |
Why?
|
| Indoleacetic Acids | 1 | 2017 | 7 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2015 | 69 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 15 | 0.140 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 80 | 0.140 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 110 | 0.140 |
Why?
|
| Australia | 4 | 2019 | 21 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2017 | 18 | 0.140 |
Why?
|
| Young Adult | 5 | 2018 | 2581 | 0.140 |
Why?
|
| Pancreas | 1 | 2017 | 58 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2018 | 245 | 0.140 |
Why?
|
| Histological Techniques | 1 | 2016 | 8 | 0.140 |
Why?
|
| Pyridines | 2 | 2014 | 99 | 0.140 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 400 | 0.140 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2016 | 4 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 44 | 0.130 |
Why?
|
| Neutrophil Infiltration | 5 | 2013 | 19 | 0.130 |
Why?
|
| Cellular Senescence | 1 | 2017 | 121 | 0.130 |
Why?
|
| Nephrectomy | 3 | 2012 | 48 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2011 | 27 | 0.130 |
Why?
|
| Purinones | 1 | 2016 | 2 | 0.130 |
Why?
|
| Eukaryotic Initiation Factor-4F | 1 | 2015 | 1 | 0.130 |
Why?
|
| Lactams | 1 | 2015 | 3 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 113 | 0.130 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 139 | 0.130 |
Why?
|
| Hot Temperature | 1 | 2016 | 84 | 0.130 |
Why?
|
| Transcriptome | 1 | 2017 | 198 | 0.130 |
Why?
|
| Paneth Cells | 2 | 2012 | 8 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2016 | 76 | 0.130 |
Why?
|
| Quinolones | 1 | 2015 | 22 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2019 | 386 | 0.130 |
Why?
|
| Phenotype | 6 | 2017 | 665 | 0.130 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 4 | 0.130 |
Why?
|
| Thiophenes | 2 | 2012 | 14 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2010 | 243 | 0.120 |
Why?
|
| Obesity | 2 | 2019 | 650 | 0.120 |
Why?
|
| Acid-Base Equilibrium | 1 | 1995 | 10 | 0.120 |
Why?
|
| Anions | 1 | 1995 | 15 | 0.120 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 11 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2011 | 122 | 0.120 |
Why?
|
| Adolescent | 7 | 2018 | 2957 | 0.120 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hydrolases | 1 | 2014 | 11 | 0.120 |
Why?
|
| Machine Learning | 1 | 2015 | 79 | 0.120 |
Why?
|
| Cell Line | 5 | 2014 | 672 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2014 | 324 | 0.120 |
Why?
|
| DNA, Protozoan | 1 | 2014 | 7 | 0.120 |
Why?
|
| Benzodioxoles | 1 | 2014 | 5 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2015 | 221 | 0.120 |
Why?
|
| Catalytic Domain | 1 | 2014 | 77 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2014 | 42 | 0.110 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 50 | 0.110 |
Why?
|
| Imidazoles | 1 | 2014 | 60 | 0.110 |
Why?
|
| Genome | 1 | 2014 | 52 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 262 | 0.110 |
Why?
|
| Oxygen | 2 | 2012 | 218 | 0.110 |
Why?
|
| Endothelium | 1 | 2013 | 28 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 246 | 0.110 |
Why?
|
| Cooperative Behavior | 2 | 2013 | 74 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 139 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 453 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 1927 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2011 | 57 | 0.110 |
Why?
|
| Electronic Nose | 1 | 2013 | 1 | 0.110 |
Why?
|
| Genotype | 4 | 2019 | 442 | 0.110 |
Why?
|
| Diet | 1 | 1995 | 223 | 0.110 |
Why?
|
| Photons | 1 | 2013 | 27 | 0.110 |
Why?
|
| RNA Splicing | 1 | 2012 | 9 | 0.100 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 11 | 0.100 |
Why?
|
| Sequence Alignment | 2 | 2014 | 110 | 0.100 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Medulloblastoma | 2 | 2003 | 18 | 0.100 |
Why?
|
| Dictyostelium | 1 | 2012 | 5 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 657 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 324 | 0.100 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 9 | 0.100 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 194 | 0.100 |
Why?
|
| Mice, Knockout | 5 | 2013 | 782 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 20 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 5 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2012 | 59 | 0.100 |
Why?
|
| Sumoylation | 1 | 2011 | 2 | 0.100 |
Why?
|
| Family | 1 | 2012 | 98 | 0.100 |
Why?
|
| Chromosome Segregation | 1 | 2012 | 55 | 0.100 |
Why?
|
| Gene Knockout Techniques | 3 | 2017 | 35 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2018 | 587 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 41 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 150 | 0.090 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 30 | 0.090 |
Why?
|
| Necrosis | 4 | 2013 | 81 | 0.090 |
Why?
|
| Proteins | 1 | 2013 | 244 | 0.090 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2010 | 23 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2010 | 2 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 8 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 151 | 0.090 |
Why?
|
| Protein Binding | 5 | 2016 | 631 | 0.090 |
Why?
|
| Algorithms | 1 | 2013 | 419 | 0.090 |
Why?
|
| Genetic Markers | 3 | 2019 | 93 | 0.090 |
Why?
|
| Loss of Heterozygosity | 3 | 2014 | 11 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2010 | 197 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2010 | 141 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 26 | 0.080 |
Why?
|
| Prognosis | 4 | 2018 | 759 | 0.080 |
Why?
|
| Feeding Behavior | 2 | 2002 | 101 | 0.080 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 8 | 0.080 |
Why?
|
| Child | 7 | 2005 | 2147 | 0.080 |
Why?
|
| Age of Onset | 1 | 2008 | 68 | 0.080 |
Why?
|
| Computational Biology | 2 | 2019 | 150 | 0.080 |
Why?
|
| Chromosome Mapping | 3 | 2017 | 130 | 0.080 |
Why?
|
| Cytokines | 1 | 2010 | 438 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2019 | 83 | 0.070 |
Why?
|
| Fetus | 1 | 2008 | 77 | 0.070 |
Why?
|
| Genes, Neoplasm | 3 | 2016 | 7 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 1393 | 0.070 |
Why?
|
| Gestational Age | 1 | 2008 | 140 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2003 | 113 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 3 | 2013 | 32 | 0.070 |
Why?
|
| Netherlands | 2 | 2019 | 6 | 0.070 |
Why?
|
| Polymorphism, Genetic | 4 | 2018 | 163 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2015 | 503 | 0.070 |
Why?
|
| Duodenal Neoplasms | 1 | 2007 | 6 | 0.070 |
Why?
|
| Capillary Permeability | 3 | 2013 | 38 | 0.070 |
Why?
|
| Denmark | 2 | 2019 | 26 | 0.070 |
Why?
|
| Frameshift Mutation | 2 | 2019 | 13 | 0.070 |
Why?
|
| Ultraviolet Rays | 2 | 2017 | 40 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2019 | 313 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 253 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 586 | 0.070 |
Why?
|
| Exome | 2 | 2019 | 29 | 0.070 |
Why?
|
| United Kingdom | 2 | 2018 | 70 | 0.070 |
Why?
|
| Patient Selection | 1 | 2007 | 143 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2008 | 205 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 82 | 0.060 |
Why?
|
| Entorhinal Cortex | 1 | 2005 | 3 | 0.060 |
Why?
|
| Neurofibrillary Tangles | 1 | 2005 | 12 | 0.060 |
Why?
|
| Gene Targeting | 2 | 2017 | 17 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 2 | 2003 | 144 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 486 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2017 | 35 | 0.060 |
Why?
|
| Transfection | 2 | 2017 | 313 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2005 | 14 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 186 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2003 | 27 | 0.060 |
Why?
|
| Fatty Acids | 2 | 2024 | 198 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 151 | 0.060 |
Why?
|
| Point Mutation | 2 | 2014 | 60 | 0.060 |
Why?
|
| Ocular Hypertension | 1 | 2004 | 11 | 0.060 |
Why?
|
| Sarcoidosis | 1 | 2004 | 38 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 36 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2024 | 14 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 284 | 0.060 |
Why?
|
| United States | 3 | 2014 | 2032 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 210 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2012 | 310 | 0.060 |
Why?
|
| Intraocular Pressure | 1 | 2004 | 61 | 0.060 |
Why?
|
| Ketoglutaric Acids | 2 | 2012 | 16 | 0.060 |
Why?
|
| Chromosomes, Human | 2 | 2015 | 31 | 0.060 |
Why?
|
| Time Factors | 2 | 2013 | 1562 | 0.060 |
Why?
|
| Enzyme Induction | 2 | 2013 | 27 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2003 | 15 | 0.050 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2003 | 3 | 0.050 |
Why?
|
| Fiji | 1 | 2003 | 1 | 0.050 |
Why?
|
| Researcher-Subject Relations | 1 | 2003 | 1 | 0.050 |
Why?
|
| Social Facilitation | 1 | 2003 | 2 | 0.050 |
Why?
|
| Mitochondria | 1 | 2006 | 333 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2003 | 28 | 0.050 |
Why?
|
| rho-Associated Kinases | 2 | 2014 | 12 | 0.050 |
Why?
|
| Adenosine A1 Receptor Agonists | 2 | 2013 | 2 | 0.050 |
Why?
|
| Astrocytoma | 1 | 2003 | 35 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2014 | 42 | 0.050 |
Why?
|
| Cholesterol, Dietary | 2 | 1999 | 6 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2003 | 95 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 60 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2013 | 110 | 0.050 |
Why?
|
| Dietary Fats | 2 | 1999 | 55 | 0.050 |
Why?
|
| Schizophrenia, Catatonic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 2 | 0.050 |
Why?
|
| Ion Channels | 1 | 2002 | 22 | 0.050 |
Why?
|
| Anorexia Nervosa | 1 | 2002 | 11 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2001 | 1 | 0.050 |
Why?
|
| Myometrium | 1 | 2001 | 7 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2001 | 6 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2001 | 12 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 58 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2002 | 74 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2001 | 57 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2001 | 61 | 0.050 |
Why?
|
| Hypercholesterolemia | 2 | 1999 | 17 | 0.050 |
Why?
|
| Alanine Transaminase | 2 | 2012 | 25 | 0.050 |
Why?
|
| Hydroxylation | 2 | 2012 | 9 | 0.050 |
Why?
|
| Neoplasms | 1 | 2010 | 755 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2001 | 53 | 0.050 |
Why?
|
| Creatinine | 2 | 2012 | 57 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 367 | 0.050 |
Why?
|
| Inservice Training | 1 | 2001 | 9 | 0.050 |
Why?
|
| Sphingosine | 2 | 2011 | 22 | 0.050 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2001 | 9 | 0.050 |
Why?
|
| Florida | 1 | 2001 | 54 | 0.050 |
Why?
|
| Blood-Borne Pathogens | 1 | 2000 | 2 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 93 | 0.050 |
Why?
|
| Hepatitis B | 1 | 2000 | 12 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2000 | 8 | 0.050 |
Why?
|
| Focus Groups | 1 | 2001 | 89 | 0.050 |
Why?
|
| Lysophospholipids | 2 | 2011 | 48 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 2 | 2019 | 64 | 0.040 |
Why?
|
| Tachycardia, Ventricular | 1 | 2001 | 60 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2001 | 163 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2001 | 150 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2000 | 57 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2000 | 38 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 264 | 0.040 |
Why?
|
| School Health Services | 1 | 2000 | 34 | 0.040 |
Why?
|
| Retina | 1 | 2004 | 421 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 980 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 33 | 0.040 |
Why?
|
| Sweden | 1 | 2019 | 3 | 0.040 |
Why?
|
| Health Personnel | 1 | 2000 | 91 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 14 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 288 | 0.040 |
Why?
|
| Dimerization | 1 | 2019 | 75 | 0.040 |
Why?
|
| ras Proteins | 1 | 2019 | 43 | 0.040 |
Why?
|
| HIV-2 | 1 | 1999 | 2 | 0.040 |
Why?
|
| Gene Products, tat | 1 | 1999 | 2 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 135 | 0.040 |
Why?
|
| Growth Substances | 1 | 1999 | 11 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2019 | 13 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 115 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2019 | 182 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 23 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 270 | 0.040 |
Why?
|
| Italy | 1 | 2018 | 13 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 12 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 472 | 0.040 |
Why?
|
| Binding Sites | 2 | 2016 | 338 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 262 | 0.040 |
Why?
|
| Mental Health | 1 | 1999 | 96 | 0.040 |
Why?
|
| HIV-1 | 1 | 1999 | 54 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2010 | 189 | 0.040 |
Why?
|
| HIV Infections | 1 | 2000 | 146 | 0.040 |
Why?
|
| Haplotypes | 2 | 2014 | 279 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1999 | 65 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2019 | 102 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 143 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 91 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 100 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 747 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2019 | 263 | 0.040 |
Why?
|
| Africa, Eastern | 1 | 2017 | 1 | 0.040 |
Why?
|
| Suppression, Genetic | 1 | 2017 | 5 | 0.040 |
Why?
|
| Antiporters | 1 | 2017 | 6 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2017 | 17 | 0.040 |
Why?
|
| Lipids | 1 | 2019 | 195 | 0.040 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2017 | 1 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 445 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2017 | 7 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2017 | 25 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2019 | 351 | 0.040 |
Why?
|
| Myosins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Organisms, Genetically Modified | 1 | 2017 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 10 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2019 | 300 | 0.040 |
Why?
|
| Family Health | 3 | 2002 | 71 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 578 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2017 | 40 | 0.040 |
Why?
|
| Leukocytes | 1 | 2017 | 67 | 0.040 |
Why?
|
| Insulin | 1 | 2019 | 310 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 1997 | 11 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 276 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 57 | 0.030 |
Why?
|
| Endonucleases | 1 | 2017 | 17 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 37 | 0.030 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2017 | 7 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1998 | 86 | 0.030 |
Why?
|
| Rats | 2 | 2004 | 1545 | 0.030 |
Why?
|
| Histones | 1 | 2017 | 90 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 10 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 12 | 0.030 |
Why?
|
| DNA Primers | 2 | 2012 | 143 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 122 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 5 | 0.030 |
Why?
|
| Oncogenes | 1 | 2016 | 34 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 44 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2016 | 20 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 34 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 20 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 43 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 62 | 0.030 |
Why?
|
| Citrates | 1 | 1995 | 2 | 0.030 |
Why?
|
| Citric Acid | 1 | 1995 | 4 | 0.030 |
Why?
|
| Succinates | 1 | 1995 | 9 | 0.030 |
Why?
|
| Succinic Acid | 1 | 1995 | 10 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 67 | 0.030 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 322 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 73 | 0.030 |
Why?
|
| Blood | 1 | 1995 | 33 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 96 | 0.030 |
Why?
|
| Israel | 1 | 2014 | 11 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 197 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2014 | 26 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 64 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2014 | 2 | 0.030 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2014 | 4 | 0.030 |
Why?
|
| Amphetamines | 1 | 2014 | 11 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2014 | 8 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2014 | 27 | 0.030 |
Why?
|
| Ethyl Methanesulfonate | 1 | 2014 | 1 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 128 | 0.030 |
Why?
|
| Genes, Protozoan | 1 | 2014 | 3 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Thymidine | 1 | 2014 | 6 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 96 | 0.030 |
Why?
|
| Gene Order | 1 | 2014 | 9 | 0.030 |
Why?
|
| Ethylnitrosourea | 1 | 2014 | 8 | 0.030 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1995 | 261 | 0.030 |
Why?
|
| Cadherins | 1 | 2014 | 24 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Amides | 1 | 2014 | 18 | 0.030 |
Why?
|
| Base Pairing | 1 | 2014 | 25 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2014 | 29 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2014 | 51 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 129 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 63 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2014 | 67 | 0.030 |
Why?
|
| DNA Repair | 1 | 2014 | 81 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 134 | 0.030 |
Why?
|
| RNA | 1 | 2014 | 104 | 0.030 |
Why?
|
| Anesthesia | 1 | 2013 | 25 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 105 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 152 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 545 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 5 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2013 | 1 | 0.030 |
Why?
|
| Volatilization | 1 | 2013 | 4 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 13 | 0.030 |
Why?
|
| Research Design | 1 | 2014 | 174 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2010 | 206 | 0.030 |
Why?
|
| Portal System | 1 | 2012 | 3 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2012 | 11 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 388 | 0.030 |
Why?
|
| Xanthines | 1 | 2012 | 3 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 69 | 0.030 |
Why?
|
| Glycosylation | 1 | 2012 | 69 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2012 | 13 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2007 | 857 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2011 | 14 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2011 | 47 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 35 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2011 | 21 | 0.020 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 7 | 0.020 |
Why?
|
| Pigmentation | 1 | 2011 | 6 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 30 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1991 | 53 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 189 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 118 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 442 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 133 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 316 | 0.020 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Papio anubis | 1 | 2010 | 40 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 4 | 0.020 |
Why?
|
| Exons | 2 | 2002 | 41 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 623 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 31 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2010 | 27 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2012 | 148 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 42 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 2010 | 3 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 21 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 44 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 46 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2010 | 66 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 153 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 16 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 273 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 40 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 72 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 80 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 93 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 298 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2007 | 2264 | 0.020 |
Why?
|
| Geography | 1 | 2009 | 47 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 147 | 0.020 |
Why?
|
| Illinois | 1 | 2007 | 3 | 0.020 |
Why?
|
| Genes, Mitochondrial | 1 | 2006 | 10 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 276 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 73 | 0.020 |
Why?
|
| Multigene Family | 1 | 2005 | 50 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2005 | 59 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 60 | 0.020 |
Why?
|
| Methotrexate | 1 | 2005 | 32 | 0.020 |
Why?
|
| District of Columbia | 1 | 2004 | 8 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 27 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 74 | 0.010 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2004 | 21 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 91 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 199 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2004 | 21 | 0.010 |
Why?
|
| Manometry | 1 | 2004 | 36 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2004 | 70 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2004 | 76 | 0.010 |
Why?
|
| Neuroglia | 1 | 2004 | 30 | 0.010 |
Why?
|
| Cisplatin | 1 | 2005 | 172 | 0.010 |
Why?
|
| Optic Nerve | 1 | 2004 | 28 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 406 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2004 | 65 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 90 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2003 | 19 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 242 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 395 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 445 | 0.010 |
Why?
|
| Serine | 1 | 2002 | 48 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2002 | 72 | 0.010 |
Why?
|
| England | 1 | 2002 | 34 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 86 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 377 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2001 | 21 | 0.010 |
Why?
|
| Estrogen Receptor beta | 1 | 2002 | 13 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 14 | 0.010 |
Why?
|
| Estrogen Receptor alpha | 1 | 2002 | 26 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2001 | 66 | 0.010 |
Why?
|
| Nitriles | 1 | 2001 | 32 | 0.010 |
Why?
|
| Finland | 1 | 2001 | 3 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 280 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 1216 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 55 | 0.010 |
Why?
|
| Myocardium | 1 | 2001 | 171 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2001 | 391 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 1 | 0.010 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 1999 | 5 | 0.010 |
Why?
|
| Gene Library | 1 | 1999 | 45 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1999 | 54 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1999 | 65 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 365 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1999 | 102 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1999 | 117 | 0.010 |
Why?
|
| Cysteine | 1 | 1999 | 67 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1999 | 73 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 1999 | 82 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1999 | 62 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 228 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 1998 | 64 | 0.010 |
Why?
|
| Educational Status | 1 | 1998 | 110 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 209 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 172 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 43 | 0.010 |
Why?
|
| Mothers | 1 | 1998 | 110 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 2433 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 508 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 918 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 1991 | 3 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1991 | 2 | 0.010 |
Why?
|
| Clone Cells | 1 | 1991 | 20 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 19 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 110 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1991 | 57 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1991 | 133 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1991 | 64 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 18 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1990 | 36 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1990 | 50 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1990 | 135 | 0.010 |
Why?
|